Biotech · Private company
Brooklyn ImmunoTherapeutics, LLC
Track this companyFree. Adds Brooklyn ImmunoTherapeutics, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials62 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- CyclophosphamidePhase 2 · Squamous Cell Carcinoma of the Oral CavityClinicalTrials.gov · fetched Nov 12, 2026
- IndomethacinPhase 2 · Squamous Cell Carcinoma of the Oral CavityClinicalTrials.gov · fetched Nov 12, 2026
- IRX-2Phase 2 · Squamous Cell Carcinoma of the Oral CavityClinicalTrials.gov · fetched Nov 12, 2026
- OmeprazolePhase 2 · Squamous Cell Carcinoma of the Oral CavityClinicalTrials.gov · fetched Nov 12, 2026
- Zinc-containing multivitaminPhase 2 · Squamous Cell Carcinoma of the Oral CavityClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 30, 2020ClinicalTrials.gov NCT04373031 · fetched Nov 12, 2026
- IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell CarcinomaPHASE1 · COMPLETED · started Aug 21, 2019ClinicalTrials.gov NCT03381183 · fetched Nov 12, 2026
- IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3PHASE2 · TERMINATED · started Nov 8, 2017ClinicalTrials.gov NCT03267680 · fetched Nov 12, 2026
- Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)PHASE1 · COMPLETED · started Feb 9, 2017ClinicalTrials.gov NCT02950259 · fetched Nov 12, 2026
- IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral CavityPHASE2 · COMPLETED · started Jan 11, 2016ClinicalTrials.gov NCT02609386 · fetched Nov 12, 2026
- Molecular Studies and Clinical Correlations in Human Prostatic DiseaseACTIVE_NOT_RECRUITING · started Apr 1, 1990ClinicalTrials.gov NCT00578240 · fetched Nov 12, 2026